Status:
COMPLETED
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Lead Sponsor:
Allergan
Conditions:
Facial Rhytides
Crow's Feet Lines
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)
Eligibility Criteria
Inclusion
- Moderate to severe Crow's Feet Lines and Frown Lines
- Have adequate vision without the use of eyeglasses to assess facial wrinkles in the mirror (contact lenses OK)
Exclusion
- Current or previous botulinum toxin treatment of any serotype
- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
- Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery)
- Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months
- Oral retinoid therapy within one year
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
917 Patients enrolled
Trial Details
Trial ID
NCT01189760
Start Date
September 1 2010
End Date
September 1 2011
Last Update
April 16 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Newport Beach, California, United States
2
Vancouver, British Columbia, Canada
3
Antibes, France
4
Berlin, Germany